Similar articles

• Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

  Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group. Reijnders JG, et al. J Hepatol. 2010 Apr;52(4):493-500. doi: 10.1016/j.jhep.2010.01.012. Epub 2010 Feb 4. J Hepatol. 2010. PMID: 20185191 Clinical Trial.
• [Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].

  Benhamou Y. Benhamou Y. Gastroenterol Clin Biol. 2006 Oct;30(10 Pt 2):3S22-5. Gastroenterol Clin Biol. 2006. PMID: 17075492 Review. French. No abstract available.
• Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.

  Leemans WF, Ter Borg MJ, de Man RA. Leemans WF, et al. Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:171-82. doi: 10.1111/j.1365-2036.2007.03481.x. Aliment Pharmacol Ther. 2007. PMID: 18081660 Review.
• Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

  Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C. Boni C, et al. Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014. Epub 2012 Jul 14. Gastroenterology. 2012. PMID: 22796241
• Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.

  Rodriguez-Frias F, Jardi R, Schaper M, Gimferrer M, Elefsiniotis I, Tabernero D, Esteban R, Buti M. Rodriguez-Frias F, et al. J Med Virol. 2007 Nov;79(11):1671-3. doi: 10.1002/jmv.20982. J Med Virol. 2007. PMID: 17854030